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Translocations involving AML1 are common in AML. 1, 2 The most frequent of these translocations fuse in-frame the DNA-binding domain of AML1 to ETO in leukemia bearing the t(8;21). AML with these translocations has a reasonably good prognosis. 1, 2 However, there have been several recent reports of AML1 translocations involving other partner genes. [3] [4] [5] [6] These other translocations involving AML1 are fairly rare. In general, these have usually occurred in secondary leukemias. All the leukemias bearing these other AML1 translocations have a dismal prognosis, in contrast to the t(8;21). Interestingly, two of these uncommon AML1 translocations fused AML1 out of frame to the partner gene. One of these, isolated from a radiation-associated secondary AML, fused the N-terminal AML1 DNA-binding domain out of frame to AMP19, which resulted in a truncated AML1 protein that inhibited activation of a myeloidspecific promoter by CBF. 6 Another of these out-of-frame AML1 fusions was found in a myelodysplasia bearing a t(3;21). 5 This fused the N-terminal AML1 DNA-binding domain out of frame to EAP, also resulting in a truncated inhibitory AML1 protein.
In this study, we found a myeloid leukemia with a t(12;21)(q12;q22) that also resulted in a truncated inhibitory AML1 protein.
A 76-year-old man presented with pancytopenia. Marrow aspirate found AML of the FAB subtype M2. Cytogenetics were initially normal, and the patient underwent induction with Ara-C and idarubicin. He achieved a remission, and was given one cycle of high-dose Ara-C consolidation. He did well for 1 year, at which time he presented with pancytopenia. Marrow aspirate found that he had relapsed. Interestingly, upon relapse, repeat cytogenetics found a t(12;21)(q12;q22) as the sole abnormality. He underwent fludarabine/Ara-C/idarubicin reinduction chemotherapy. He cleared the leukemic blasts from his marrow, and was discharged. However, he remained moderately cytopenic after reinduction, with dysplastic features in his peripheral blood cells. He ultimately succumbed to an opportunistic infection.
FISH on the relapsed leukemic marrow found that the telomeric (5 0 ) portion of the AML1 gene was reciprocally translocated to 12q12 ( Figure 1 ). Using RACE PCR, 6 the partner gene in this translocation was cloned and found to be a previously undescribed member of the copine family we termed copine VIII (GenBank # AY177785, mouse homologue AK004559). The 5' telomeric portion (DNA-binding domain) of AML1 was broken after exon 6 and fused to the intron 2 sequence from the Copine VIII gene (Figure 1b) , near the amino terminus of the protein. Three independent RACE reactions obtained the same breakpoint sequence, and the same breakpoint sequence could be amplified using primers from AML1 and Copine VIII (Figure 2a ). Copine VIII is 564 amino acid (aa) in length and shares 52% identity with Copine III and 50% identity with Copine I. The reciprocal product, Copine VIII-AML1, would be conceptually fused in frame but was not expressed as determined by RT-PCR (Figure 2a) . The Copine VIII gene has 18 exons and spans 251 916 nucleotides of 12q. Copine VIII appears to be widely expressed in many tissues at low levels by RT-PCR analysis.
The AML1 fusion with Copine VIII is out of frame, resulting in a translational termination after 2 aa of Copine VIII. This would produce a truncated AML1 protein that contains only the DNAbinding domain and not the transactivation domain. Such a protein could bind to CBF target myeloid promoters, but not transactivate them. Thus, it would serve as an inhibitor of CBF activity. 1, 2, 4, 6 This hypothesis was tested using cotransfection assays with the M-CSF receptor promoter as a reporter as we described. 6 The M-CSF receptor is a known target for activation by CBF. The cotransfection assays found that CBF activation of the M-CSF receptor promoter was inhibited up to 3.4-fold by AML1-Copine VIII (Figure 3) . This is the third AML1 translocation that is fused out of frame to a partner gene, generating a truncated AML1 protein. The other two are AML1 -EAP, and AML1-AMP19. 4, 6 All these three cases with the truncated AML1 species had elements hematopoietic dysplasia. These truncated AML1 species likely played a role in the myelodysplastic phenotype seen in each of these cases, by inhibiting the normal CBF activation of myeloid-specific genes. Such inhibition would prevent the maturation of hematopoietic progenitors, resulting in abnormal myeloid development. In that Figure 1 FISH analysis of the leukemic marrow showing the AML1 translocation. The green signal is TEL on chromosome 12, and the red signal is AML1. There are three red signals, indicating that one AML1 allele is split by translocation. Chromosome 12 in the center of the photomicrograph that has both the red (on 12q) and the green signal (on 12p) represents the translocation.
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manner, these truncated AML1 species may be more similar to the inhibitory point mutations seen in a fraction of myelodysplasia and leukemia than they are to translocations producing fusion proteins. 2 Taken together with the emerging data on AML1 point mutations, it is clear that truncated AML1 without the transactivation capability represents an additional mechanism by which AML1 can contribute to leukemogenesis.
It has been hypothesized that AML requires two genetic lesions, one that stimulates proliferation (Type I) and one that blocks differentiation (Type II). 2 These truncated AML1 species would behave like a Type II genetic lesion, and block differentiation. However, while they could produce a myelodysplastic phenotype of pancytopenia due to an inhibition of maturation, it is likely that these truncated AML1 species require the addition of a Type I lesion to produce frank acute leukemia. Nonetheless, these truncated AML1 fusion proteins represent an emerging and intriguing genetic lesion in myeloid leukemias.
In this leukemia, the AML1 gene was fused to a novel member of the copine family. This poorly understood protein family has not yet been linked to neoplasia. Copines are calcium-binding membraneassociated proteins that can regulate plant cell proliferation by unknown mechanisms. 7, 8 Like the other members of this family, Copine VIII has two C2 domains that are shared by the protein kinase C family, and a VWF domain. It is possible that Copine VIII is a negative regulator of cell proliferation, and its disruption by this translocation confers an additional proliferative mutation. If that were the case, then this single translocation would fulfill the requirements for both a Type I and II genetic lesion for leukemogenesis. The Copine VIII disruption would increase proliferation and the AML1 truncation would block differentiation. Thus, one could speculate that a single translocation could produce haploinsufficiency of both a tumor suppressor and also an inhibitor of maturation. Proof of this intriguing concept will await generation of animal models of Copine VIII deletion into which AML1 truncated species could be introduced in hematopoietic progenitors. 
